CSPC Pharma receives USD 25 million R&D milestone payment from AstraZeneca under collaboration deal

• CSPC received a USD 25 million R&D milestone payment from AstraZeneca on July 10 under their strategic collaboration and license agreement.
• The payment follows receipt of an upfront payment on May 29 tied to the same deal to develop long-acting peptide medicines.
• CSPC cited the milestone as a sign the agreed R&D work is progressing in line with plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260710-12241897), on July 10, 2026, and is solely responsible for the information contained therein.